Skip to main content
. 2020 Apr;6(2):a004838. doi: 10.1101/mcs.a004838

Table 1.

Clinical case characteristics

Case Age (years), sex Clinical manifestation prior to EMS diagnosis Karyotype Treatments Outcome
Case 1 58, male AML 47, XY, t(8;22) (p11.2; q11.2), +19[20] 1. Sorafenib and 7 + 3
2. ASCT
3. FLAG-IDA		 Originally, CR with MRD negative status
Relapse 5 mo and death 6 mo after presentation
Case 2 72, female B-ALL 46, XX, t(8;22), del(9), del(16), and del (7) 1. Hyper-CVAD-A and rituximab
2. Hyper-CVAD-B and methotrexate
3. FLAG-IDA		 Originally, CR with MRD negative status
Death 6 mo after presentation

(CR) Complete remission, (MRD) minimal residual disease, (7 + 3) cytarabine (7 d) + anthracycline (3 d), (FLAG-IDA) fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor (G-CSF), (Hyper-CVAD-A) cyclophosphamide, vincristine, doxorubicin, and dexamethasone, (Hyper-CVAD-B) methotrexate and cytarabine.